retatrutide clinical trials retatrutide Subcutaneous Fat Loss Results: What Reveal About Effectiveness and Safety Retatrutide Phase 3: TRIUMPH Program

Achieving the right balance between cost and long-term health outcomes requires a holistic view of the benefits program grounded in data and tailored to the unique needs of the workforce. Editors Note: Additional Content For more information and resources related to this article, see the pages below, which offer quick access to all WorldatWork content on these topics: #1 Total Rewards & Comp Newsletter Subscribe to Workspan Weekly and always get the latest news on compensation and Total Rewards delivered directly to you

0 g Protein

The glucagon receptor arm the feature that distinguishes retatrutide from earlier-generation incretin compounds drives hepatic glucose metabolism, lipid oxidation, and energy expenditure effects, all absent from GLP-1 mono-agonists and dual GLP-1/GIP agonists

Microdosing GLP-1 means using doses significantly below the approved therapeutic range, but this practice lacks clinical trial evidence and is not approved by the MHRA

While only a small proportion of adolescents and young adults currently receive both therapies, combination treatment was virtually nonexistent before GLP-1 medications became widely available